---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-018428"
form_type: "8-K"
ticker: "MTNB"
cik: "0001582554"
company_name: "Matinas BioPharma Holdings, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:59:04.915813+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Matinas BioPharma Q1 2024 net loss $5.8M; raises $10M in April, expects cash into Q2 2025

## Summary
- Q1 2024 revenue $0 vs $1.1M in Q1 2023; net loss $5.8M ($0.03 per share).
- Cash and equivalents $8.1M at March 31, 2024; subsequent $10M registered direct offering in April 2024.
- Active partnership discussions to advance MAT2203 into Phase 3 ORALTO trial in invasive aspergillosis.
- Compassionate use program has enrolled 22 patients with severe fungal infections; LNC platform abstracts at ASGCT.

## SEC filing metadata
- accession: 0001493152-24-018428
- form_type: 8-K
- ticker: MTNB
- cik: 0001582554
- company_name: Matinas BioPharma Holdings, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582554/000149315224018428/0001493152-24-018428-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582554/000149315224018428/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-018428
- JSON: https://secwatch.observer/filing/0001493152-24-018428.json
- Plain text: https://secwatch.observer/filing/0001493152-24-018428.txt

## Key facts
- Earnings Releases
  Matinas BioPharma Holdings, Inc. reported the three months ending March 31, 2024 results: revenue no revenue for the first quarter of 2024, net income net loss for the first quarter of 2024 was $5.8 million, or $0.03 per share, EPS $0.03 per share.
  - Period: the three months ending March 31, 2024
  - Revenue: no revenue for the first quarter of 2024
  - Net income: net loss for the first quarter of 2024 was $5.8 million, or $0.03 per share
  - EPS: $0.03 per share
  - Result: reported results
  source text: Matinas BioPharma Holdings, Inc . (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports financial results for the three months ending March 31, 2024 and provides a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582554/000149315224018428/0001493152-24-018428-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.